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Receptor internalization in response to prolonged agonist treatment is an important regulator 
of G protein-coupled receptor (GPCR) function. The adenosine A1 receptor (A1AR), is one of 
the adenosine receptor family of GPCRs, and evidence for its agonist-induced internalization 
is equivocal. The recently developed NanoBiT technology utilizes split NanoLuc luciferase to 
monitor changes in protein interactions. We have modified the human A1AR on the N-terminus 
with the small high affinity HiBiT tag. In the presence of the large NanoLuc subunit (LgBiT) 
complementation occurs, reconstituting a full-length functional NanoLuc luciferase. Here, we 
have used complemented luminescence to monitor the internalization of the adenosine A1 
receptor in living HEK293 cells. Agonist treatment resulted in a robust decrease in cell-surface 
luminescence, indicating an increase in A1AR internalization. These responses were inhibited 
by the A1AR-selective antagonist DPCPX with an antagonist affinity that closely matched that 
measured using ligand-binding with a fluorescent A1-receptor antagonist (CA200645). The 
agonist potencies for inducing A1AR internalization were very similar to the affinities previously 
determined by ligand-binding, suggesting little or no amplification of the internalization 
response. By complementing the HiBiT tag to exogenous purified LgBiT it was also possible 
to perform NanoBRET ligand-binding experiments using HiBiT-A1AR. This study 
demonstrates the use of NanoBiT technology to monitor internalization of the adenosine A1 







G protein-coupled receptors (GPCRs) are the largest family of membrane signalling proteins 
and are able to modulate signals from a wide range of endogenous ligands1. Prolonged 
stimulation by an agonist results in the internalization of many GPCRs, and this process can 
occur via different pathways, including caveolae-dependent and clathrin-mediated 
processes2,3. For the latter, G protein-coupled receptor kinases (GRKs) phosphorylate serine 
and threonine residues within the intracellular loops and C-terminal tail of the receptor 
following agonist-stimulated receptor activation4. β-Arrestins are able to bind to the 
phosphorylated receptor and can initiate downstream signalling pathways which are 
independent of G proteins5. β-Arrestins also compete sterically with G proteins for binding to 
the receptor, resulting in receptor desensitization, and recruit specific adaptor proteins which 
are required for clathrin-mediated endocytosis6. The GPCRs are internalized in clathrin-coated 
vesicles and transferred into early endosomes, where it is now known that a second wave of 
intracellular signalling can occur7,8. 
The adenosine A1 receptor (A1AR) is part of the wider adenosine GPCR subfamily, grouped 
by their ability to bind their endogenous ligand, adenosine1,9. The A1AR predominantly couples 
to the Gi family of heterotrimeric G proteins which inhibit adenylyl cyclase mediated cAMP 
production. However, there is contrasting evidence concerning the nature of GRK-mediated 
A1AR phosphorylation10-13, as well as the nature and extent of A1ARs internalization in 
response to chronic stimulation by agonists12-15. The A1AR is able to internalize through both 
clathrin- and caveolae-dependent endocytosis13,16. Previous studies of human A1AR 
internalization observed that the receptor had a slow rate of internalization over several 
hours15,17-19. Ruiz et al. (2011) found this was also true of the rat A1AR receptor which required 
over 12 hours stimulation to internalize 50% of rat A1ARs in cortical neurons20. These A1AR 
data contrast drastically with the other Gi-coupled adenosine receptor, the A3 receptor, which 
internalizes more rapidly, and within minutes of agonist stimulation12,21,22.  
Previous studies on A1AR internalization have been conducted using either radiolabelled A1AR 
ligands14,15 or with confocal microscopy11,19. These techniques offer specific advantages, such 
as the ability to monitor A1AR internalization in ex vivo tissues with radioligand binding, or the 
ability to directly visualize internalization with microscopy. However, these methods are 
intensive and low throughput. 
Recently, NanoLuc binary technology (NanoBiT®) has been developed that splits the bright 
NanoLuc luciferase23 into two segments, a large 18 kDa fragment (termed LgBiT), and much 
smaller 1.3 kDa fragment termed SmBiT (small complementation tag)24. These fragments 
have low intrinsic affinity for each other (KD 190 µM) and complement to form the full 
bioluminescent protein NanoLuc. SmBiT-LgBiT complementation has successfully been used 
to monitor protein-protein interactions of membrane receptors, including the recruitment of G 
proteins and β-arrestins to GPCRs25,26.  In the development of the NanoBiT system, other 
small complementary peptides were identified which have different affinities for LgBiT. One 
short, 11 amino acid sequence had a very high affinity for LgBiT (KD 700 pM, termed HiBiT24). 
As an 18 kDa fragment, the LgBiT is cell impermeable and therefore HiBiT-LgBiT 
complementation provided an approach to distinguish between internalized proteins and those 
retained at the cell surface. This would not have been possible with the full-length NanoLuc 
luciferase. In this study, we have used A1ARs tagged on the N-terminus with HiBiT to 
determine whether NanoBiT complementation can be used as a high throughput method to 
monitor loss of A1ARs from the cell surface in living cells.   
  
Materials and Methods 
Materials. 
Adenosine and 5’-N-ethylcarboxamidoadenosine (NECA) were purchased from Sigma-Aldrich 
(Gillingham, UK). 1,3,-Dipropyl-8-cyclopentylxanthine (DPCPX), 2-chloro-N6-
cyclopentyladenosine (CCPA), 2’methyl-2-chloro-N6-cyclopentyladenosine (2-MeCCPA), and 
2-phenylaminoadenosine (CV 1808) were obtained from Tocris (Bristol, UK). 2-Amino-6-[[2-
(4-chlorophenyl)-1,3-thiazol-4-yl]methylsulfanyl]-4-[4-(2-hydroxyethoxy)phenyl]pyridine-3,5-
dicarbonitrile (capadenoson) was purchased from Haoyuan Chemexpress (Shanghai, China). 
The fluorescent antagonist CA200645 was purchased from HelloBio (Bristol, UK). Purified 
LgBiT, restriction enzymes, FuGENE HD transfection reagent, and furimazine were purchased 
from Promega (Southampton, UK). 
Constructs and Cell Lines. 
To create the HiBiT-A1AR construct, the full length NanoLuc sequence was removed from the 
pcDNA3.1 NLuc-A1AR vector27 using KpnI and BamHI restriction sites. This left the pcDNA3.1 
vector containing the A1AR with a mutated start codon (Met -> Leu). Primers containing the 
HiBiT sequence (bold letters), a GSSGGSSG linker (5’: 
cATGGTGAGCGGCTGGCGGCTGTTCAAGAAGATTAGCGGGAGTTCTGGCGGCTCGAG
CGGTg; and 5’:  
gatccACCGCTCGAGCCGCCAGAACTCCCGCTAATCTTCTTGAACAGCCGCCAGCCGCT
CACCATggtac) and the repective KpnI and BamHI overhangs (lower case letters) were 
phosphorylated using T4 Polynucleotide kinase (NEB, UK) and annealed for 30 minutes at 
37°C. The annealed primers were then ligated into the digested pcDNA3.1 A1AR vector using 
T4 ligase (NEB, UK) creating the full-length fusion protein HiBiT-A1AR. Correct insertion was 
confirmed by DNA sequencing using the School of Life Sciences Sequencing Facility at the 
University of Nottingham. 
HEK293 cells were maintained in Dulbecco’s modified eagle medium (DMEM) containing 10% 
fetal calf serum (FCS) and 2 mM L-glutamine at 37°C in a 5% CO2 atmosphere.  A mixed 
population HiBiT-A1AR stable cell line was generated using FuGENE HD (Promega) according 
to the manufacturer’s instructions and the cells were subjugated to three week’s selection with 
1 mg/mL G418. 
NanoBiT Internalization Assay. 
HEK293 cells stably expressing HiBiT-A1AR were plated onto white 96-well plates (Greiner) 
previously coated with 10 µg/mL poly-D-lysine. 100 µL DMEM containing cells in suspension 
(30,000 cells/well) was added to each well and the plate incubated at 37°C in a 5% CO2 
atmosphere for 24 hours. The next day, the media was removed from each well and replaced 
with 50 µL HEPES-buffered saline solution (HBSS; 145 mM NaCl, 5 mM KCl, 10 mM HEPES, 
1.3 mM CaCl2 dihydrate, 1.5 mM NaHCO3, 2 mM sodium pyruvate, 1 mM MgSO4.7H2O, 
10 mM D-glucose; pH 7.45) and the relevant concentration of ligand. For end-point assays 
cells were incubated at 37°C for 2 hours. Purified LgBiT was diluted in HBSS (10 nM final 
concentration) and added to each well in the presence of furimazine (1:400 final 
concentration). The plate was incubated for 15 minutes in the dark at 37°C, allowing 
complementation to occur. Luminescence was measured on the PHERAstar FS plate reader 
(BMG Labtech) using the LUM Plus module.  
Bioluminescence Imaging. 
HEK293 cells stably expressing HiBiT-A1AR were seeded onto a poly-D-lysine coated (10 
µg/mL) 35 mm 4-chamber MatTek dish (Ashland, MA, USA) at a density of 120,000 cells/mL. 
The dish was incubated at 37°C in a 5% CO2 atmosphere for 24 hours. The next day the media 
was removed and replaced with 400 µL HBSS containing furimazine (1:400 final 
concentration). Purified LgBiT was added and the plate incubated at 37°C for 20 minutes. 
Brightfield and bioluminescence imaging was performed on the Olympus LV200 inverted 
microscope (Olympus, Southend, UK). Brightfield images were captured with a 50 ms 
exposure. Bioluminescence images were captured with a 45 s exposure, using a Hamamatsu 
EM CCD with a gain of 100. 
NanoBRET Ligand-binding assay. 
HEK293 HiBiT-A1AR cells were seeded onto poly-D-lysine-coated white 96-well plates as 
described above. The next day, the media was removed from each well and replaced with 50 
µL HBSS containing 10 nM LgBiT and the plate was incubated for 15 minutes in the dark at 
37°C, allowing complementation to occur. The HBSS with unbound LgBiT was removed and 
replaced with 50 µL HBSS containing the fluorescent A1-receptor antagonist ligand 
CA20064528 in the absence or presence of 10 µM DPCPX. The plate was incubated in the 
dark at 37°C for 2 hours.  Furimazine (1:400 final concentration) was added to each well and 
the plate incubated for 15 minutes at 37°C. The resulting BRET was measured using the 
PHERAstar FS plate reader (BMG Labtech) which simultaneously measured filtered light 
emissions at 460 (80 nm bandpass) and >610 nm (longpass). The BRET ratio was calculated 
by dividing the >610 nm emission by the 460 nm emission. 
Data analysis. 
Data were presented and analysed using Prism 7 software (GraphPad). 
The potency of ligands which internalized HiBiT-A1AR were determined from fitting data to a 
one-site sigmoidal concentration-response curve defined by the following four parameter 
logistic equation: 
Eq. (1)  %	#$%$&'(#	)'	%$**	+,#-)%$ = 100 −	 (344×[78]);[78]<=>?@8 A + CD 
where [A] is the concentration of the ligand, NS is background luminescence, n is the Hill 
coefficient, and IC50 is the concentration of ligand required to internalize 50% of receptors. 
In the experiments where three fixed concentrations of DPCPX were used, the KD of DPCPX 
was estimated from the shift in the NECA response by 10 nM DPCPX using the Gaddum 
equation29: 
Eq. (2)  CR = 1 + [G]HI  
where CR is the concentration ratio of NECA required to stimulate an identical response in the 
presence or absence of 10 nM DPCPX [B], and KB is the affinity of DPCPX. 
The time course of internalization in response to 10 µM NECA at HiBiT-A1AR was fitted with 
a one-phase exponential decay curve using the following equation: 
Eq. (3)  J = (J4 − CD)KL.N + CD 
where Y is the luminescence at time t minutes, Y0 was the luminescence at time 0, NS is the 
background luminescence, and k is the rate constant of the decrease in luminescence per 
minute. 
Saturation NanoBRET experiments were simultaneously fitted to obtain the total and 
nonspecific components using the following equation: 
Eq. (4)  OPQR	P)'S( =	 GTUV×[G][G]<HW + ((X × [O]) + Y) 
where Bmax is the maximal level of specific binding, [B] is the concentration of fluorescent ligand 
in nM, KD is the equilibrium dissociation constant, M is the slope of the linear nonspecific 
binding component, and C is the y-axis intercept. 
Data are presented as mean ± s.e.m. of triplicate determinations in a single experiment. In the 
text, n refers to the number of separate experiments. Statistical significance was defined as 
p<0.05 using Student’s unpaired t-test.  
Results 
NanoLuc Binary Technology (NanoBiT) has provided a platform for assessing protein-protein 
interactions in vitro in real-time24,30-32. Here, we have used the NanoBiT complementation 
technology to monitor the presence of the human A1-receptor, tagged on its N-terminus with 
HiBiT, at the cell surface of living cells following addition of purified LgBiT (Figure 1a). This 
approach can also be extended to detect the loss of HiBiT-A1AR following agonist stimulation 
as a method to detect receptor internalization (Figure 1b). 
Expression of the HiBiT-A1AR at the plasma membrane was first confirmed using NanoBiT 
complementation. HEK293 cells stably transfected with HiBiT-A1AR were incubated with 
purified LgBiT in the presence of the NanoLuc substrate, furimazine. As an 18 kDa protein, 
LgBiT is cell impermeable, and thus will only complement with HiBiT-A1AR present on the 
plasma membrane.  Increasing concentrations of LgBiT resulted in higher luminescence signal 
(Figure 2a, n=4). These results indicated that HiBiT-A1AR was able to traffic to the plasma 
membrane and complement with exogenously applied purified LgBiT. It should be noted that 
neither HiBiT-A1AR nor LgBiT alone produced a strong luminescent signal (Figure 2a). 
Widefield bioluminescent imaging also confirmed clear membrane expression of HiBiT-A1AR 
in HEK293 cells (Figure 2b). From these experiments, it was determined that 10 nM LgBiT 
would provide a sufficient luminescence response window for all subsequent assays. 
To confirm that the complementation of HiBiT-A1AR with exogenously applied LgBiT did not 
alter the ability of the A1-AR to bind ligands, ligand binding studies were performed using 
NanoBRET with a fluorescent A1-antagonist28,33 (Figure 1a).  Following complementation of 
HiBiT-A1AR with purified LgBiT, the binding of the fluorescent A1-receptor antagonist 
CA200645 to the complemented A1-receptor was monitored using NanoBRET28 (Figure 1; 
Figure 3). In these assays, clear specific binding of CA200645 was observed to the A1AR. The 
negative log of the dissociation constant (pKD) of CA200645 was calculated to be 7.17 ± 0.03 
(KD 63.8 nM; n=4; Figure 3). This was similar to the KD value reported previously (KD 33.8 nM) 
for CA200645 to the full length NanoLuc-tagged A1AR27. 
With successful membrane expression of HiBiT-A1AR confirmed, it was then established if 
NanoBiT could be used to monitor receptor internalization (Figure 1b). Cells were incubated 
at 37°C and treated with 10 µM NECA for increasing periods of time to stimulate an 
internalization response. Longer incubation periods resulted in a decrease in luminescence 
(Figure 4), correlating to an increase in the proportion of HiBiT-A1ARs which have internalized 
(Figure 1b). The resulting half-life of internalization was 31 ± 6 minutes (n=4). From these 
data, a 2-hour ligand incubation time was chosen for all subsequent end-point experiments, 
as receptor internalization had plateaued by this point. 
NECA stimulated a concentration-dependent loss of HiBiT-A1ARs from the cell surface of 
HEK293 cells (pIC50 of 5.67 ± 0.21, n=10; Figure 5a, Table 1).  The A1-selective antagonist 
DPCPX was able to inhibit the NECA-stimulated internalization response (Figure 5a). Fitting 
the Gaddum equation to the responses measured in the presence and absence of 10 nM 
DPCPX produced an affinity of DPCPX (pKD 8.28 ± 0.12, n=6) which closely matches the 
affinity of DPCPX calculated at the human NLuc-A1AR27. 
A panel of adenosine A1 receptor agonists were screened for their ability to internalize HiBiT-
A1AR. In addition to NECA, the A1AR agonists CCPA and 2-MeCCPA were found to be full 
agonists in this assay, able to stimulate a robust internalization of HiBiT-A1AR (Figure 5b, 
Table 1). The atypical A1AR agonist capadenoson, and the adenosine A2 receptor ligand CV-
1808 were found to elicit partial internalization responses (Figure 5b, Table 1).  
  
Discussion 
NanoBiT has provided the opportunity to measure GPCR-effector interactions in real-time in 
living cells with a high degree of sensitivity25,26,31,32. Here, we have used the high affinity HiBiT 
tag to detect cell surface expression of the adenosine A1 receptor and quantified the loss of 
receptors at the cell surface in response to agonist treatment as a measure of receptor 
internalization. 
The HiBiT-A1AR was successfully expressed on the surface of HEK293 cells and could be 
visualized with bioluminescent imaging following addition of exogenous purified LgBiT. 
Furthermore, the complemented NLuc-A1AR retained the ability to bind fluorescent adenosine 
A1AR antagonists yielding binding constants that were similar to those determined previously 
using A1ARs expressing the full length NLuc tag27,28. The strong luminescence signal provided 
by fully complemented HiBiT-LgBiT, however, provided a large assay window to detect small 
changes in the surface expression of the A1AR. This can be observed in Figure 4 as the loss 
of luminescence in response to increasing incubation periods with the agonist NECA. 
The human adenosine A1 receptor has been shown to internalize in recombinant cell lines 
using radioligand binding15,17,18. These studies observed a slow rate of A1AR internalization, 
with t1/2 for internalization in the order of several hours. Using NanoBiT it was possible to detect 
A1AR internalization (Figure 4) at much earlier time points than was previously reported17-19. 
Additionally, both radioligand binding and confocal microscopy are low-throughput techniques 
and not amenable to performing full concentration-response curves for a panel of A1AR 
agonists.  
In contrast, NanoBiT provided an ideal platform for detecting the internalization of A1AR in 
living cells in response to a wide panel of ligands. The high signal-to-noise ratio of the assay 
made it possible to monitor full agonist and partial agonist responses over relatively short 
periods of time (Figure 5b). The potencies of the agonist responses were generally similar to 
the affinities of the ligands at the human A1AR as measured previously with NanoBRET27. 
Thus, the similarity in values obtained for NECA and CCPA for the two assays suggests that 
there is no signal amplification in the internalization response for these two agonists. This 
contrasts with the higher receptor-effector coupling observed for these ligands for cAMP 
inhibition or pERK1/2 phosphorylation34,35.  
The one exception was the partial A1AR agonist capadenoson36,37 where the pEC50 (5.23) for 
internalization was over an order of magnitude lower that its pKi value (6.85) determined from 
inhibition of NanoBRET binding with CA200645 at the human A1AR27. This very low potency 
for internalization of capadenoson compared to its binding affinity for the orthosteric ligand-
binding site suggests that there may be a more complex mechanism of action involved.  This 
may involve differential affinities for multiple A1AR agonist receptor conformations and the 
potential for signalling bias35,38,39.   
The internalization stimulated by NECA could be antagonised by the A1AR antagonist DPCPX 
in a concentration-dependent manner. The resulting analysis suggested an affinity for DPCPX 
which was in keeping with the known affinity of this ligand for the human A1AR27,40. 
Additionally, there was no hint of inverse agonism with DPCPX in this assay (Table 1).  
These experiments were performed in HEK293 cells, which express both adenosine A2A and 
A2B receptors endogenously41. It is unlikely that the internalization responses measured in this 
study were affected by the presence of the adenosine A2A or A2B receptors, given the potencies 
of the ligands used in this study are in the same rank order of the binding affinities of the 
human A1AR27,40,42, and the affinity for DPCPX determined was in keeping with the known 
affinity at the human A1AR.   
It should be noted that the assay described here has been configured specifically to monitor 
the extent of loss of A1-receptors from the cell surface in response to agonist treatment. From 
the data obtained, we cannot comment on the extent to which A1-agonists also alter A1-
receptor protein degradation and turnover.  However, it should be noted that NanoBiT 
represents a versatile technology with a broad dynamic range which can be applied to detect 
and quantify protein expression30 and degradation43. For example, Riching et al. have 
exploited the high sensitivity of HiBiT-LgBiT complementation to detect targets with low levels 
of native expression, and measure their subsequent degradation following PROTAC 
treatment43. A similar approach using  a HiBiT tag on the C-terminus of the A1-receptor and its 
expression in cells that also express cytosolic LgBiT would allow A1-receptor turnover and 
degradation to be monitored.  
In conclusion, this study reports the use of NanoBiT to monitor A1AR internalization in a plate-
based assay based on complemented nanoluciferase luminescence. This approach can 
readily be applied to other GPCRs or indeed any cell surface membrane receptors (e.g. 
receptor tyrosine kinase or cytokine receptor) through the introduction of the HiBiT-tag at the 
extracellular terminus of the protein of interest. 
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Table 1 – pEC50 and Emax values of agonist-induced internalization of HiBiT-A1AR in HEK293 cells. Data are mean ± SEM from n separate 
experiments. †Internalization stimulated by the highest concentration (100 µM) of this ligand (p<0.05 comparing Emax vs that of 100 µM NECA). 
Ligand 
Internalization pEC50 
(mean ± SEM) 
Emax (% 100 µM NECA) n 
NECA 5.67 ± 0.21 100 10 
Capadenoson 5.23 ± 0.32 57.8 ± 4.4† 5 
CCPA 6.43 ± 0.18 84.4 ± 6.5 10 
2-MeCCPA 4.96 ± 0.13 86.7 ± 4.1 5 








Figure 1. (a) Schematic of the use of NanoBiT complementation to monitor the expression of 
HiBiT-A1AR at the cell surface.A1ARs tagged with HiBiT on their N terminus are expressed at 
the cell surface of HEK293 cells. Upon addition of exogenous purified LgBiT, complementation 
occurs between HiBiT and LgBiT, forming the full-length NLuc luciferase. In the presence of 
the substrate, furimazine, the complemented NLuc is luminescent. Addition of a red A1-
receptor fluorescent ligand such as CA200645 that binds to the HiBiT-tagged A1AR allows 
NanoBRET to occur between the NLuc and the fluorescent ligand. (b) Schematic of the 
NanoBiT internalization assay. Under basal conditions, N-terminally HiBiT-tagged A1ARs are 
expressed on the plasma membrane of HEK293 cells. Upon addition of exogenous purified 
LgBiT, complementation occurs between HiBiT and LgBiT, forming the full-length NLuc 
luciferase. In the presence of the substrate, furimazine, luminescence is read as the 
experimental output. When treated with an agonist, the HiBiT-A1AR undergoes internalization 
and is removed from the plasma membrane. After two hours, purified LgBiT is added to the 
media, but it cannot cross the plasma membrane and complement with the HiBiT-A1AR, and 
therefore there is less complemented NLuc as a result. 
Figure 2.  (a) The effect of purified LgBiT titrations on complemented luminescence in HEK293 
cells stably expressing HiBiT-A1AR following 15 minutes incubation with furimazine (1:400). 
Bars indicate the luminescence measured by 200 nM LgBiT (open bar) and HiBiT-A1AR 
(closed bar) alone, respectively. Data are mean ± SEM from triplicate determinations in a 
single experiment. This single experiment is representative of four independent experiments 
performed. (b) Widefield bioluminescence imaging of HEK293 cells stably expressing HiBiT-
A1AR with increasing concentrations of purified LgBiT. Cells were incubated with LgBiT and 
furimazine (1:400) for 20 minutes prior to imaging. Images are representative of three separate 
experiments. Scale bars show 20 µm. 
Figure 3.  NanoBRET ligand binding at the A1AR using fully complemented HiBiT-LgBiT. 
10 nM LgBiT was first added to HEK293 cells stably expressing HiBiT-A1AR before addition 
of increasing concentrations of CA200645 for two hours. Non-specific binding was determined 
in the presence of 10 µM DPCPX. Data are mean ± SEM from triplicate determinations in a 
single experiment. This single experiment is representative of four independent experiments 
performed.  
Figure 4.  Timecourse of HiBiT-A1AR internalization in HEK293 cells. Luminescence of cell 
surface complemented HiBiT-LgBiT in cells treated with 10 µM NECA for up to 4 hours. Data 
are mean ± SEM of triplicate determinations from a single experiment. This single experiment 
is representative of five separate experiments. 
Figure 5. (a) Ability of DPCPX to inhibit the NECA-induced internalization response in HiBiT-
A1AR. Internalization of HiBiT-A1AR in response to NECA in the absence or presence of the 
antagonist DPCPX at 10, 30, 100 nM, respectively. Data are mean ± SEM from triplicate 
determinations in a single experiment. This single experiment is representative of six separate 
experiments. (b) Concentration response curves of HiBiT-A1AR internalization stimulated by 
a panel of A1-receptor agonists in HEK293 cells. Internalization is reported as a percentage of 
internalization stimulated by a two hour incubation with 100 µM NECA. Data are mean ± SEM 
from least five separate experiments, where each experiment was performed in triplicate. The 
number of individual experiments performed with each agonist is given in Table 1. 
 
 
 





